Harvard Bioscience (HBIO) Shares Outstanding (Diluted Average) (2010 - 2026)

Harvard Bioscience (HBIO) has 15 years of Shares Outstanding (Diluted Average) data on file, last reported at $4.5 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $4.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (changed N/A YoY), and the FY2025 annual result was $44.4 million, up 1.96% from the prior year.
• Shares Outstanding (Diluted Average) eased to $4.5 million in Q1 2026 per HBIO's latest filing, from $44.4 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $44.4 million in Q4 2025 and troughed at $664000.0 in Q1 2023.
• A 5-year average of $34.7 million and a median of $42.4 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) declined 0.84% in 2023, then jumped 6436.45% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $41.4 million in 2022, then grew by 2.43% to $42.4 million in 2023, then grew by 2.64% to $43.5 million in 2024, then gained by 1.96% to $44.4 million in 2025, then slumped by 89.92% to $4.5 million in 2026.
• Business Quant data shows HBIO's Shares Outstanding (Diluted Average) at $4.5 million in Q1 2026, $44.4 million in Q4 2025, and $43.5 million in Q4 2024.